CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
May 25th 2024
Intimacy was always important in my relationship with my husband, and it continued to be even after my small lymphocytic lymphoma diagnosis.
An ‘Equal Playing Field’ Makes up the Available Treatment Options for CLL
February 27th 2022Regardless of a patient’s age, comorbidity status or disease risk, an expert from Memorial Sloan Kettering Cancer Center notes how targeted therapies have become the standard of care in treating chronic lymphocytic leukemia.
Calquence Linked to Fewer Heart-Related, Other Toxicities in Patients With CLL Than Imbruvica
January 7th 2022Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.
Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL
December 14th 2021The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.
Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia
April 23rd 2021Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.